The prolonged wait for an effective remedy for non-alcoholic steatohepatitis (NASH) has concluded with the FDA’s approval of the inaugural drug for this fatty liver condition. Madrigal Pharmaceuticals’ resmetirom, soon available as Rezdiffra, has achieved the milestone of becoming the primary therapy for NASH to receive FDA clearance, after a protracted journey through drug development.
On March 14, 2024, the FDA greenlit this tablet medication for treating NASH, in cases of moderate to severe liver scarring, or fibrosis, at stages F2 and F3. The anticipated acceptance of Rezdiffra is poised to pave the way for forthcoming NASH treatments, establishing a standard ...
